|
|
Evax-B |
|
Vaxjo ID |
156 |
|
Vaccine Adjuvant Name |
Evax-B |
|
Adjuvant VO ID |
VO_0005510
|
|
Description |
yeast derived Botryococcene oil-in-water emulsion that induces TH1/TH2 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (Evax Inc. Lexington KY) |
|
Host Species for Testing |
Mouse |
|
Components |
isomer of squalene that is generated when the two precursor molecules, farnesyl diphosphate (FPP), are conjugated in an asymmetrical manner unlike squalene, giving rise to a more branched triterpene oil |
|
Preparation |
introduction of a full-length B. braunii squalene synthase gene into yeast and extracting by adding hexane and acetone and extracting |
|
Function |
Mimic of MF59/Addavax with a proprietary squalene |
| References |
(Kempinski, 2024): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=101]
Tateno et al., 2020: Tateno M, Stone BJ, Srodulski SJ, Reedy S, Gawriluk TR, Chambers TM, Woodward J, Chappell J, Kempinski CF. Synthetic Biology-derived triterpenes as efficacious immunomodulating adjuvants. Scientific reports. 2020; 10(1); 17090. [PubMed: 33051497].
|
|
